Fig. 1

Expression patterns and clinical correlations of PABPC5 in glioma. (A) Box plot showing the expression levels of PABPC5(log2 transformed) across glioma grades (G2–G4) from The Cancer Genome Atlas (TCGA) cohort, indicating a highly significant difference between Grades (B) The box plot illustrating PABPC5 expression in different molecular subtypes of glioblastoma (GBM) was evaluated using TCGA datasets. Significant differences in expression were observed among the subtypes (mesenchymal, proneural, and neural), and ANOVA analysis confirmed statistical significance. (C) Representative images from IHC assays specimens of 60 archived glioma cases (G1 n = 17, G2 n = 13, G3 n = 19, G4 n = 11; Amplification: ×200; ×400; A negative control group is shown for reference.) The associated box plot quantifies the mean proportion of PABPC5 positive area across different glioma grades. (D) Western blotting was employed to detect PABPC5 protein expression levels in gliomas of varying grades. The graph below the blot quantifies the relative expression of PABPC5, β-actin was uesd as the loading control. The data indicate that PABPC5 protein expression was significantly elevated in higher grade gliomas compared to low-grade gliomas. (E) Kaplan-Meier survival analysis was performed based on PABPC5 expression levels in glioma patients. High expression of PABPC5 (red line) has a tredn toward worse survial outcomes, but did not reach statistical significance (P = 0.92) (ns:P>0.05, ^*P < 0.05, ^**P < 0.01, ^***P < 0.001).